Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

Also called NCT05050500

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 143 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05050500
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05050500. Randomized; triple masking; primary purpose treatment. Start 2023-05-08 (actual); primary completion 2024-12-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
Condition
Diabete Type 2
Condition
Glucose Intolerance
Intervention (Drug)
Dapagliflozin 10mg/Tab
Intervention (Drug)
control group
Lead sponsor
Qingdao Central Hospital (class: other)

Record details

Record id
cardio:ct-nct05050500
Content hash
2c25b96d2bba27241c34360c93246761bb14c1bee2abdc62c04351152b6e15fd